Aurinia Pharmaceuticals (AUPH) opened Q1 2026 with total revenue of US$77.7 million, basic EPS of US$0.26, and trailing 12 month EPS of US$2.25, following a year in which earnings grew very sharply and the company moved to a 100% net margin. The company has seen quarterly revenue move from US$59.9 million in Q4 2024 to US$62.5 million in Q1 2025 and then to US$77.7 million in Q1 2026, while basic EPS has shifted over the same period from US$0.01 to US$0.17 and then to US$0.26. This has set up a results season in which investors are weighing rich trailing profitability against concerns about earnings quality and how sustainable current margins really are.

See our full analysis for Aurinia Pharmaceuticals.

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the widely followed narratives about Aurinia, and where the story that investors tell themselves might need to be updated.

TTM profit at 100% margin, but Q4 spike stands out

• Over the last 12 months, Aurinia reported net income of US$298.2 million on US$298.3 million of revenue, giving a 100% net margin. Q4 2025 alone contributed US$210.8 million of that profit on US$77.1 million of revenue.
• Bulls point to this very high trailing profitability as proof that Aurinia has turned a corner, yet:
  • Reported earnings growth of very large multiples year over year sits alongside disclosure that a significant portion of profit comes from non cash items, which can make current margins hard to repeat.
  • Even with that strong trailing profit, consensus forecasts show average earnings declines of 3.4% per year over the next three years, so the bullish view leans heavily on the idea that product adoption and cost control will offset those headwinds.

Curious how this profit spike fits into the most optimistic long term story investors are debating around Aurinia right now? 🐂 Aurinia Pharmaceuticals Bull Case

Revenue momentum versus bearish margin worries

• Quarterly revenue has moved from US$59.9 million in Q4 2024 to US$62.5 million in Q1 2025, US$70.0 million in Q2 2025, US$73.5 million in Q3 2025, US$77.1 million in Q4 2025 and US$77.7 million in Q1 2026. Revenue is forecast to grow about 11.6% per year.
• Bears focus on the risk that current profitability does not hold as the business grows, and the numbers highlight that tension clearly:
  • Forecasts call for earnings to decline by an average of 3.4% per year even as revenue is expected to keep growing, which lines up with the cautious narrative that margins could compress from current levels.
  • Critics also flag the heavy reliance on one commercial product and non cash earnings in past periods, which, combined with the expected drop from a 100% net margin, underpins concerns about how resilient profits will be if competition or pricing pressure increases.

Skeptics argue those revenue forecasts are not enough if margins reset sharply, so it helps to see how the more cautious analysts frame that risk in full. 🐻 Aurinia Pharmaceuticals Bear Case

Low 6.6x P/E against DCF fair value

• With a current share price of US$15.14 and trailing EPS of US$2.25, Aurinia trades on a P/E of 6.6x, which is below the US Biotech industry average of 17.8x and the cited peer average of 35.6x, and well under the stated DCF fair value of US$43.44.
• The consensus narrative treats this gap as a mix of opportunity and caution:
  • Supporters highlight that the stock price is below both the analyst price target of US$17.00 and the DCF fair value of US$43.44, which they see as compensation for the risk that earnings ease back from unusually high trailing margins.
  • On the other hand, the same forecasts that point to revenue growth of about 11.6% per year also show declining earnings, which can help explain why the market keeps the multiple low even with a very large year over year profit improvement on paper.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Aurinia Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both clear risks and real rewards on the table, sentiment around Aurinia is understandably mixed. Move quickly, review the data for yourself, and weigh the 4 key rewards and 2 important warning signs

See What Else Is Out There

Aurinia’s heavy reliance on non cash driven earnings, expectations for earnings declines, and questions around margin sustainability all point to elevated risk for cautious investors.

If that mix of fragile profits and forecast earnings pressure worries you, it is worth comparing Aurinia with companies screened for resilience using the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.